Safety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 portion of a global, double-blind, randomised, placebo-controlled trial
Modupe Idowu(The University of Texas Health Science Center at Houston), Wally R. Smith(Virginia Commonwealth University), Rolandas Urbstonaitis(Agios Pharmaceuticals (United States)), Deepika S. Darbari(Children's National), Adlette Inati(Rafik Hariri University), Lucas Otieno(United States Army Medical Research Directorate - Africa), Pablo Bartolucci(European Organisation for Rare Diseases), Hui Shao(University of Louisville), Susan Morris(Agios Pharmaceuticals (United States)), Abdulafeez Oluyadi(Agios Pharmaceuticals (United States)), Amber M. Yates(Baylor College of Medicine), Kenneth I. Ataga(University of Tennessee Health Science Center), Bülent Antmen(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Kevin H.M. Kuo(University Health Network), Sarah Gheuens(Biogen (United States)), Ahmar U. Zaidi(Agios Pharmaceuticals (United States)), Alì Taher(American University of Beirut Medical Center), Miguel R. Abboud(American University of Beirut Medical Center), Swee Lay Thein(National Heart Lung and Blood Institute), Raffaella Colombatti(University of Padua), Spurthi Patil(Agios Pharmaceuticals (United States)), Biree Andemariam(UConn Health), Alexander Glaros(Central Michigan University), Samuel de Souza Medina(Universidade Estadual de Campinas (UNICAMP)), Clarisse L. C. Lobo(Hemorio), Obiageli Nnodu(University of Abuja), Varsha Iyer(Agios Pharmaceuticals (United States)), Bogdan Dumitriu(National Heart Lung and Blood Institute)
Cited by 25
Related Papers
Sickle cell disease
|Nature Reviews Disease Primers|2018|1.4k
Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study
|The Lancet|2011|1.3k
Immune dysregulation in human subjects with heterozygous germline mutations in <i>CTLA4</i>
|Science|2014|844
Thalassaemia
|The Lancet|2017|763